$47.62−1.18 (−2.42%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Enliven Therapeutics (ELVN) Institutional Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
Sources Ownership filingsQuarter ended How we compute thisNot investment advice
5 figures withheld by our checks. Each blank figure names its reason.
13F fund flowQuarter ended Jun 30, 2026*. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 214 filers, Jun 30, 2026
# 13F FUNDS
214
13F VALUE
$4.1B
80.5M shares
Withheld: the 13F filers report more shares than the company has outstanding, which happens when shared or lent shares are counted twice. The filer count, shares and value are as filed.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Kunkel Lori Anne | director | Acquired · Option exercise | 3,741 | $1.12 | ↗ |
| Oct 30, 2026 | Kunkel Lori Anne | director | Acquired · Option exercise | 7,300 | $18.30 | ↗ |
| Oct 30, 2026 | Kunkel Lori Anne | director | Disposed · Option exercise | 3,741Stock Option (right to buy) | — | ↗ |
| Oct 30, 2026 | Kunkel Lori Anne | director | Disposed · Option exercise | 7,300Stock Option (right to buy) | — | ↗ |
| Oct 19, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Acquired · Option exercise | 6,018 | $14.85 | ↗ |
| Oct 19, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 6,018 | $38.48 | ↗ |
| Oct 19, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Disposed · Option exercise | 6,018Stock Option (right to buy) | — | ↗ |
| Oct 19, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Acquired · Option exercise | 5,000 | $2.48 | ↗ |
| Oct 19, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Disposed · Open-market sale | 5,000 | $38.47 | ↗ |
| Oct 19, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Disposed · Option exercise | 5,000Stock Option (right to buy) | — | ↗ |
| Oct 14, 2026 | BALL KRISTINE M | director | Acquired · Grant / award | 23,394Stock Option (right to buy) | — | ↗ |
| Oct 1, 2026 | Garland J. Scott | director | Acquired · Option exercise | 13,000 | $15.47 | ↗ |
| Oct 1, 2026 | Garland J. Scott | director | Disposed · Open-market sale | 13,000 | $46.67 | ↗ |
| Oct 1, 2026 | Garland J. Scott | director | Disposed · Option exercise | 13,000Stock Option (right to buy) | — | ↗ |
| Aug 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 4,630 | $58.35 | ↗ |
| Aug 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 1,388 | $59.35 | ↗ |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Acquired · Option exercise | 5,000 | $2.48 | ↗ |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Disposed · Open-market sale | 3,900 | $58.37 | ↗ |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Disposed · Open-market sale | 1,100 | $59.35 | ↗ |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Disposed · Option exercise | 5,000Stock Option (right to buy) | — | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How many 13F filers hold Enliven Therapeutics?
Enliven Therapeutics was held by 214 13F filers as of Jun 30, 2026.
Not investment advice.

